Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2019-01-29Clinical Trial Update: Vestibular Rehabilitation for Persons With Multiple Sclerosis: Who Benefits the Most? (MSVR3trial) [NA]
A completed clinical trial (MSVR3) evaluating vestibular rehabilitation in people with multiple sclerosis to determine which patients benefi…
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Central Pain Study for ABX-1431 [Phase 1]
Phase 1 central pain study of ABX-1431 conducted by Abide Therapeutics has completed.
-
CLINICAL_TRIALS trial_result · 2019-01-25Clinical Trial Update: Assessing Fatiguability of Tongue Muscles in MS [NA]
A clinical trial sponsored by Thomas More Kempen is assessing fatigability of tongue muscles in people with Multiple Sclerosis to explore sw…
-
FDA approval · 2019-01-25FDA Approved: TIZANIDINE — Original Application (Ascend Laboratories, LLC)
FDA approved Ascend Laboratories, LLC's original ANDA for tizanidine, establishing a generic version of the muscle relaxant.
-
CLINICAL_TRIALS trial_result · 2019-01-23Clinical Trial Update: Feasibility and Reliability of Multimodal Evoked Potentials
This completed clinical trial assesses the feasibility and reliability of multimodal evoked potentials in individuals with multiple sclerosi…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2019-01-22Clinical Trial Update: Dietary Supplement of Curcumin in Subjects With Active Relapsing Multiple Sclerosis Treated With Subcutaneous Interferon Beta 1a [Phase 2]
Phase 2 trial evaluating a curcumin dietary supplement in patients with active relapsing multiple sclerosis treated with subcutaneous interf…
-
CLINICAL_TRIALS trial_result · 2019-01-18Clinical Trial Update: MEasuring Satisfaction of Treatment With REbif After Initial Treatment of Multiple Sclerosis (MS)
A clinical trial evaluating satisfaction with Rebif after initial treatment for multiple sclerosis was terminated. Results were posted on 20…
-
FDA approval · 2019-01-16FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)
FDA overview of a supplemental application for CAMPATH (alemtuzumab) submitted by Genzyme Corporation.
-
FDA approval · 2019-01-11FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCL) from Novartis Pharmaceuticals Corporation.
-
FDA approval · 2019-01-07FDA Approved: TERIFLUNOMIDE — Original Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare's generic teriflunomide through an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2018-12-19Clinical Trial Update: Interferon ß-1b Treatment by Cyclical Administration [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating cyclical interferon β-1b treatment for multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2018-12-11Clinical Trial Update: Masitinib in Primary Progressive Multiple Sclerosis or Relapse-free Secondary Progressive Multiple Sclerosis [Phase 2]
Phase 2 trial update for masitinib in primary progressive or relapse-free secondary progressive multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2018-12-07Clinical Trial Update: Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis [Phase 4]
Phase 4 clinical trial evaluating alemtuzumab on MRI surrogate markers of disease activity and repair in relapsing remitting multiple sclero…
-
FDA approval · 2018-11-30FDA Approved: TERIFLUNOMIDE — Original Application (Zydus Pharmaceuticals USA Inc.)
The FDA has approved a generic version of teriflunomide for relapsing forms of multiple sclerosis, filed by Zydus Pharmaceuticals USA Inc.
-
FDA approval · 2018-11-23FDA Approved: BACLOFEN — Original Application (Zydus Pharmaceuticals (USA) Inc.)
FDA approved the Original Application for Baclofen from Zydus Pharmaceuticals (USA) Inc., establishing a generic baclofen product. Baclofen …
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) [Phase 3]
Phase 3 trial update of BG00012 (Dimethyl Fumarate) in Asian subjects with relapsing-remitting multiple sclerosis (RRMS) has completed.
-
CLINICAL_TRIALS trial_result · 2018-11-20Clinical Trial Update: Aspirin as a Pre-Treatment for Exercise in Multiple Sclerosis [EARLY_Phase 1]
Early phase 1 trial investigating aspirin as a pre-treatment to exercise in individuals with fatigue-related symptoms in multiple sclerosis.
-
CLINICAL_TRIALS trial_result · 2018-11-19Clinical Trial Update: Thyroid Hormone for Remyelination in Multiple Sclerosis (MS): A Safety and Dose Finding Study [Phase 1]
Phase 1 safety and dose-finding study of thyroid hormone for remyelination in multiple sclerosis completed; results posted in 2018.
-
FDA approval · 2018-11-15FDA Approved: TERIFLUNOMIDE — Original Application (Glenmark Pharmaceuticals Inc., USA)
The FDA approved Glenmark's generic teriflunomide under an Original Application (ANDA 209663), enabling market entry for a generic version o…
-
FDA approval · 2018-11-12FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Ocrevus (ocrelizumab) submitted by Genentech, Inc.
-
CLINICAL_TRIALS research · 2018-11-06Clinical Trial Update: Long-Term Effects of Torso-Weighting [NA]
Clinical trial update on long-term effects of torso-weighting in multiple sclerosis; study completed with results posted in 2018.
-
CLINICAL_TRIALS trial_result · 2018-10-29Clinical Trial Update: Safety and Tolerability Study of MEDI-551, a B-cell Depleting Agent, to Treat Relapsing Forms of Multiple Sclerosis [Phase 1]
Phase 1 safety and tolerability study of MEDI-551, a B-cell depleting agent, for relapsing forms of multiple sclerosis completed with result…
-
FDA approval · 2018-10-26FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCl) submitted by Novartis Pharmaceuticals Corporation. This action repr…
-
FDA approval · 2018-10-26FDA Approved: TERIFLUNOMIDE — Original Application (Aurobindo Pharma Limited)
The FDA approved Aurobindo Pharma Limited's original application for a generic teriflunomide product. This approval makes a generic version …
-
CLINICAL_TRIALS trial_result · 2018-10-18Clinical Trial Update: Evaluate Safety and Efficacy of Apitox Add-on Therapy for Improving Disability and Quality of Life in MS Patients [Phase 3]
Phase 3 clinical trial evaluating safety and efficacy of Apitox as an add-on therapy to improve disability and quality of life in multiple s…